ArticleScientific reports2026
Antibody-functionalized gold nanospheres for multimodal imaging.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The first near-infrared (NIR-I) spectral window (700-900 nm) enables deeper tissue penetration and reduced autofluorescence, improving sensitivity for in vivo imaging. However, the relatively low fluorescence intensity of many NIR fluorophores limits their effectiveness. Here, we report the development of gold nanodye (AuND) by conjugating gold nanospheres (AuNSs) with IRDye 800 NHS ester via polyethylene glycol (PEG) linkers and functionalizing them with epidermal growth factor receptor (EGFR) targeting antibodies (Anti-AuND). This design enhances fluorescence emission through plasmonic interactions while simultaneously exploiting the high X-ray attenuation of gold for computed tomography (CT) contrast. Using Anti-AuND, we established a multimodal imaging platform integrating CT, NIR fluorescence, and fluorescence lifetime (FLT) imaging in a preclinical mouse model of EGFR-overexpressing head and neck cancer. Anti-AuND enabled high-sensitivity, high-resolution tumor visualization in vivo. The combined imaging approach provides complementary anatomical and molecular information, highlighting the potential of Anti-AuND for early cancer detection and translational biomedical imaging applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.